Larimar Therapeutics, Inc.
LRMR
$3.47
$0.3511.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.18% | -2.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 78.11% | -10.89% | |||
| Operating Income | -78.11% | 10.89% | |||
| Income Before Tax | -82.23% | 10.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -82.23% | 10.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -82.23% | 10.58% | |||
| EBIT | -78.11% | 10.89% | |||
| EBITDA | -78.35% | 10.92% | |||
| EPS Basic | -48.99% | 10.68% | |||
| Normalized Basic EPS | -48.94% | 10.66% | |||
| EPS Diluted | -48.99% | 10.68% | |||
| Normalized Diluted EPS | -48.94% | 10.66% | |||
| Average Basic Shares Outstanding | 22.33% | 0.10% | |||
| Average Diluted Shares Outstanding | 22.33% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||